News

SILIQ is indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have

Takeda president and CEO Christophe Weber said: “We are very pleased to have completed the acquisition of Ariad Pharmaceuticals. The addition of Ariad’s innovative targeted therapies and research

The firm has announced top-line results from ORAL Strategy, a Phase 3B/4 study of Xeljanz (tofacitinib citrate) 5mg twice daily (BID) in the treatment of moderate to severe rheumatoid

Pfizer has been fined £84.2m and Flynn Pharma £5.2m after they increased prices by as much as 2,600% in September 2012. The companies have separately filed appeals in the Competition Appeal

Versant seeded Jecure as part of the firm’s push to build on its past success in the fibrosis field, and was the sole investor in today’s $20m series

The multi-target expansion builds on the parties’ existing discovery and license partnership, entered into in December 2014, and was facilitated by Johnson & Johnson Innovation. This latest agreement

Tenapanor works by blocking the NHE3 sodium transporter in the gastrointestinal (GI) tract, reducing the absorption of dietary sodium resulting in increased protons within the cells. In the

Headline results were announced in December 2016 and detailed study results are being presented at the annual Conference on Retroviruses and Opportunistic Infections in Seattle. Use of dolutegravir

Adding to a pre-existing MSA for in vivo services, the terms of this agreement now covers a range of Horizon’s in vitro service offerings, defining the pricing and